EyePoint Pharmaceuticals, Inc. (EYPT)

NASDAQ: EYPT · Real-Time Price · USD
5.83
-0.08 (-1.35%)
At close: Mar 28, 2025, 4:00 PM
5.98
+0.15 (2.53%)
After-hours: Mar 28, 2025, 6:20 PM EDT
-1.35%
Market Cap 400.69M
Revenue (ttm) 43.27M
Net Income (ttm) -130.87M
Shares Out 68.73M
EPS (ttm) -2.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 370,090
Open 5.90
Previous Close 5.91
Day's Range 5.82 - 6.09
52-Week Range 5.54 - 23.65
Beta 1.42
Analysts Strong Buy
Price Target 25.71 (+341.0%)
Earnings Date Mar 5, 2025

About EYPT

EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related ma... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 27, 2005
Employees 165
Stock Exchange NASDAQ
Ticker Symbol EYPT
Full Company Profile

Financial Performance

In 2024, EyePoint Pharmaceuticals's revenue was $43.27 million, a decrease of -5.97% compared to the previous year's $46.02 million. Losses were -$130.87 million, 84.9% more than in 2023.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for EYPT stock is "Strong Buy." The 12-month stock price forecast is $25.71, which is an increase of 341.00% from the latest price.

Price Target
$25.71
(341.00% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

WATERTOWN, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives o...

3 days ago - GlobeNewsWire

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of pati...

13 days ago - GlobeNewsWire

EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2024 Earnings Call Transcript

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2024 Earnings Conference Call March 5, 2025 8:30 AM ET Company Participants George Elston - EVP and CFO Jay Duker - President and CEO Ramiro Ribeiro - ...

25 days ago - Seeking Alpha

EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments

– Enrollment exceeding expectations in DURAVYU ™ Phase 3 wet AMD clinical trials with LUGANO over 50% enrolled and LUCIA recruiting ahead of schedule – – Positive Phase 2 VERONA clinical trial of DURA...

25 days ago - GlobeNewsWire

EyePoint Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives o...

26 days ago - GlobeNewsWire

EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025

WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...

4 weeks ago - GlobeNewsWire

EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference

– Company presentation scheduled on Tuesday, March 4 th at 9:10am ET – – EyePoint to provide enrollment update for ongoing DURAVYU™ Phase 3 pivotal program in wet AMD and additional subgroup analyses ...

4 weeks ago - GlobeNewsWire

EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections required compared to Eylea and Vabysmo. Positive Phase 2 DME data and ongoin...

2 months ago - Seeking Alpha

EyePoint to Present at Guggenheim SMID Cap Biotech Conference

WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...

2 months ago - GlobeNewsWire

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D.

WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...

2 months ago - GlobeNewsWire

EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration

– Topline data for Phase 3 pivotal program anticipated in 2026 – WATERTOWN, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing an...

4 months ago - GlobeNewsWire

EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity

EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME, with one phase 3 trial ongoing and one more planned for 2025. EYP-1901 demonstrated strong safety...

4 months ago - Seeking Alpha

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...

5 months ago - GlobeNewsWire

EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...

5 months ago - GlobeNewsWire

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering

WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...

5 months ago - GlobeNewsWire

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...

5 months ago - GlobeNewsWire

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema

- DURAVYU 2.7mg demonstrated an early and sustained improvement in BCVA with a gain of +8.9 letters compared to baseline -

5 months ago - GlobeNewsWire

EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration

– Second Phase 3 LUCIA pivotal trial first patient dosing expected by end of 2024 – – Topline data anticipated in 2026 – WATERTOWN, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, I...

5 months ago - GlobeNewsWire

EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

- Appointment strengthens leadership team as Company approaches dosing of patients in Phase 3 pivotal trials of DURAVYU™ in wet AMD in 2024 - - Appointment strengthens leadership team as Company appro...

7 months ago - GlobeNewsWire

EyePoint Pharmaceuticals: After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)

EyePoint Pharmaceuticals' Duravyu shows promise as a long-acting therapy for Wet AMD, potentially rivaling Regeneron's Eylea with its six-month dosing frequency. Positive Phase 2 Davio study data boos...

7 months ago - Seeking Alpha

EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

WATERTOWN, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...

8 months ago - GlobeNewsWire

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024

WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the...

10 months ago - GlobeNewsWire

EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

WATERTOWN, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patie...

10 months ago - GlobeNewsWire

EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments

– Company on track to initiate the Phase 3 LUGANO pivotal non-inferiority trial of DURAVYU ™ in wet AMD in 2H 2024 –

11 months ago - GlobeNewsWire

EyePoint Stock: NPDR Endpoint Miss Is A Buying Opportunity Based On Lead Program

Despite NPDR primary endpoint miss, potential exists with EyePoint Pharmaceuticals releasing 12-month phase 2 PAVIA data; potential for continued advancement depending upon data. LUGANO and LUCIA are ...

11 months ago - Seeking Alpha